List of Excipients in Branded Drug SUNOSI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Jazz Pharmaceuticals Inc	SUNOSI	solriamfetol	68727-350	FERRIC OXIDE YELLOW
Jazz Pharmaceuticals Inc	SUNOSI	solriamfetol	68727-350	HYDROXYPROPYL CELLULOSE
Jazz Pharmaceuticals Inc	SUNOSI	solriamfetol	68727-350	MAGNESIUM STEARATE
Jazz Pharmaceuticals Inc	SUNOSI	solriamfetol	68727-350	POLYETHYLENE GLYCOL 3350

SUNOSI Excipient Strategy and Commercial Opportunities

Last updated: September 30, 2026

SUNOSI (solriamfetol hydrochloride) is an immediate-release, small-molecule tablet with a relatively simple excipient profile. The commercial opportunity is strongest in generic immediate-release tablets, excipient-qualified manufacturing, dose-flexible products, and differentiated oral formulations. The main barriers are controlled-substance handling, bioequivalence, solriamfetol’s pharmacokinetic profile, and remaining Orange Book patent claims rather than complex excipient technology.

What is SUNOSI and how is it regulated?

SUNOSI is approved by the FDA for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea in adults. Jazz Pharmaceuticals markets the product as 75 mg and 150 mg oral tablets. FDA approval occurred on June 17, 2019.[1]

Attribute	SUNOSI
Active ingredient	Solriamfetol hydrochloride
Drug class	Dopamine and norepinephrine reuptake inhibitor
Dosage form	Immediate-release tablet
Strengths	75 mg and 150 mg
Approved indications	Excessive daytime sleepiness in narcolepsy or obstructive sleep apnea
Initial adult dose	37.5 mg for narcolepsy; 37.5 mg or 75 mg for obstructive sleep apnea
Maximum dose	150 mg once daily
FDA pathway	New drug application
Controlled-substance status	Schedule IV
Reference product sponsor	Jazz Pharmaceuticals
Biosimilar pathway	Not applicable
Generic pathway	Abbreviated New Drug Application

SUNOSI is a small molecule, not a biologic. Biosimilar competition is therefore irrelevant. Generic applicants must generally pursue an ANDA and demonstrate pharmaceutical equivalence, bioequivalence, and compliance with applicable labeling and manufacturing requirements.

What excipients are used in SUNOSI tablets?

The FDA-approved product contains conventional solid-oral excipients. The inactive ingredient profile is publicly identified in the prescribing information and DailyMed labeling.[2]

Excipient	Likely formulation function
Mannitol	Diluent and tablet-mass builder
Microcrystalline cellulose	Diluent, compression aid, and structural excipient
Croscarmellose sodium	Superdisintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Iron oxide yellow	Colorant

The formulation does not depend on a novel delivery vehicle, lipid system, polymeric extended-release matrix, enteric coating, or biologically derived excipient. That profile lowers the technical barrier to generic development.

The exact quantities, particle-size specifications, granulation parameters, compression force, coating process, and manufacturing order are not disclosed in the public label. Those process variables can still affect dissolution, tablet robustness, content uniformity, and bioequivalence.

How strong is the excipient strategy for SUNOSI?

The reference formulation has several commercial strengths.

Immediate-release performance

SUNOSI is designed for once-daily immediate-release administration. Generic developers can potentially reproduce the dosage form with established excipient platforms used across oral solid-dose products.

The key development targets are:

• Rapid and consistent disintegration
• Comparable dissolution across relevant pH conditions
• Adequate tablet hardness and friability
• Uniform distribution of the active ingredient
• Stable color and appearance
• Low risk of magnesium-stearate over-lubrication
• Consistent performance after exposure to humidity

Because the formulation uses common excipients, the central development problem is process control rather than excipient discovery.

Dose flexibility

SUNOSI tablets are scored, and the approved labeling permits dose titration. A generic manufacturer that reproduces score performance accurately can support flexible dosing without developing multiple additional strengths.

The 75 mg and 150 mg presentations create opportunities for:

• A matched two-strength product line
• A 150 mg tablet designed for accurate splitting
• A lower-strength product optimized for initiation and titration
• Hospital or specialty-pharmacy packaging that reduces medication errors

A 37.5 mg dose may be achieved by splitting the 75 mg tablet where permitted by the approved labeling. A separately marketed 37.5 mg strength would require a distinct regulatory and commercial rationale.

Conventional excipient supply chain

Mannitol, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, and iron oxide yellow are available from multiple qualified suppliers. This creates sourcing flexibility but limits the ability of an excipient supplier to obtain product-specific exclusivity.

The highest-value excipient opportunities are therefore likely to involve:

• Low-variability direct-compression grades
• Moisture-controlled mannitol and cellulose
• Custom particle-size distributions
• Improved flow and blending performance
• Excipient packages optimized for high-dose uniformity
• Dual-source qualification for supply continuity
• Regulatory support for global filings

A supplier that sells only commodity excipient volume is unlikely to create a defensible SUNOSI-specific position. A supplier that provides formulation, process, and regulatory support has a stronger commercial proposition.

What formulations are protected by SUNOSI patents?

The public commercial formulation is a conventional immediate-release tablet. No public information establishes that the commercial opportunity depends on a separate, highly specialized excipient patent estate.

The principal intellectual-property risks are more likely to involve:

• Solriamfetol composition or salt claims
• Methods of treating excessive daytime sleepiness
• Narcolepsy and obstructive sleep apnea use claims
• Dosage and administration claims
• Listed patents in the FDA Orange Book
• Jazz-related licensing or enforcement rights

The Orange Book should be used to identify the patents currently listed for SUNOSI and the applicable use codes. Orange Book listings can change through patent expiry, delisting, corrections, or product-label updates.[3]

IP category	Relevance to excipient strategy
Active-ingredient patents	High impact on generic launch timing
Method-of-use patents	May require a Paragraph IV or section viii strategy
Formulation patents	Potentially relevant, but no public basis supports assuming a novel excipient platform
Manufacturing patents	Could affect process replication or alternate-route development
Excipient composition claims	No established public basis for treating these as the main barrier
Trade secrets	May cover process controls, specifications, and scale-up parameters

A generic manufacturer can often avoid infringement of narrow formulation claims by using a different excipient ratio, compression process, coating system, or manufacturing route. That strategy still requires equivalent product performance and may increase development cost.

When does SUNOSI lose exclusivity?

SUNOSI’s five-year new chemical entity exclusivity ran from FDA approval on June 17, 2019, and expired on June 17, 2024.[1] NCE exclusivity prevents submission of an ANDA for four years and generally prevents FDA approval of an ANDA for five years, subject to the statutory Paragraph IV exception.

The end of NCE exclusivity does not eliminate patent barriers. Generic approval timing depends on:

1. Orange Book-listed patents.
2. The applicant’s Paragraph IV certifications.
3. Patent litigation.
4. Any 30-month stay.
5. Court decisions or settlement terms.
6. Regulatory exclusivity or labeling restrictions still in effect.

Milestone	Date or status
FDA approval	June 17, 2019
Five-year NCE exclusivity	Expired June 17, 2024
Earliest ordinary ANDA submission	After four-year NCE submission bar, subject to applicable patent certifications
Commercial generic entry	Dependent on patents, litigation, settlement, and FDA approval
Biosimilar entry	Not applicable

Which companies are challenging SUNOSI?

Publicly available commercial and regulatory records should be reviewed for current ANDA applicants, Paragraph IV notices, and litigation involving Jazz Pharmaceuticals or its licensees. The competitive field is expected to include large generic manufacturers with experience in controlled substances and CNS products.

The most credible potential challengers are companies with:

• DEA-registered manufacturing capacity
• Controlled-substance inventory controls
• Established CNS commercial infrastructure
• Experience with immediate-release tablets
• Capability to support Paragraph IV litigation
• Specialty-pharmacy distribution
• Ability to conduct comparative dissolution and bioequivalence programs

A generic applicant may use one of several certification strategies:

Strategy	Commercial consequence
Paragraph III certification	Approval delayed until the relevant patent expires
Paragraph IV certification	Potential earlier approval, but creates litigation risk
Section viii statement	May permit approval for non-patented uses if labeling can be carved out
Design-around formulation	May reduce formulation-patent exposure but requires new development work

Method-of-use claims can be commercially important because SUNOSI has two approved disease settings. A skinny-label strategy could be relevant if a listed patent covers only one indication and the remaining labeling can be legally separated. The feasibility depends on the exact Orange Book use code and FDA labeling requirements.

What commercial opportunities exist for SUNOSI excipients?

Generic tablet development

This is the largest identifiable opportunity. A developer can use the reference excipient classes while optimizing:

• Tablet weight
• Disintegration time
• Dissolution profile
• Mechanical strength
• Blend uniformity
• Stability under accelerated conditions
• Manufacturing yield

The product’s conventional composition makes it suitable for development by established oral-solid-dose CDMOs.

Excipient supplier partnerships

Excipient suppliers can pursue supply agreements based on validated performance rather than molecule-specific exclusivity. Commercial differentiation may come from:

• Compendial compliance
• Nitrosamine and elemental-impurity controls
• Low microbial burden
• Consistent particle morphology
• Global regulatory documentation
• Dual-site manufacturing
• Technical support during scale-up

The most defensible supply position would combine a qualified excipient grade with a customer’s validated process. Switching suppliers after approval can trigger comparability, stability, and regulatory assessment.

Alternative oral presentations

Potential development concepts include:

• Orally disintegrating tablets
• Multiparticulates
• Sprinkle formulations
• Smaller tablets for patients with swallowing difficulty
• Unit-dose blister packs
• Abuse-deterrent or tamper-resistant presentations

These products would require a clear clinical or adherence benefit. A new dosage form could also create new patentable subject matter, but it would face additional bioequivalence, stability, manufacturability, and labeling requirements.

Specialty packaging

SUNOSI is a Schedule IV controlled substance under the Controlled Substances Act.[4] Packaging and distribution systems can therefore have commercial value. Opportunities include:

• Unit-dose compliance packs
• Tamper-evident packaging
• Blister systems that support titration
• Serialization-ready specialty-pharmacy formats
• Packaging that separates initiation and maintenance doses

Packaging does not remove controlled-substance obligations, but it can improve dispensing controls and adherence.

What manufacturing and IP barriers affect generic SUNOSI entry?

The principal manufacturing barriers are operational.

Controlled-substance compliance

Manufacturers must manage procurement, storage, production records, inventory reconciliation, security, and distribution controls. These requirements raise fixed costs and favor established controlled-substance manufacturers.

Bioequivalence and dissolution

A generic product must match the reference product’s release behavior closely enough to support ANDA approval. Changes in excipient grade, lubricant concentration, or compression process can affect dissolution and tablet disintegration.

Active-ingredient sourcing

Solriamfetol hydrochloride supply must meet identity, assay, impurity, residual-solvent, and stability requirements. A second-source API strategy can reduce supply risk but may require additional characterization.

Patent and labeling risk

Even when the tablet is technically simple, a generic applicant may face patent litigation, restricted-label requirements, or delayed approval. The commercial value of an early Paragraph IV launch depends on whether the applicant obtains first-filer status and whether the patent dispute produces a settlement or judgment.

How does SUNOSI compare with competing wake-promoting drugs?

Product	Active ingredient	Dosage form	Regulatory and formulation profile
SUNOSI	Solriamfetol	Immediate-release tablet	Conventional tablet; Schedule IV
NUVIGIL	Armodafinil	Tablet	Small-molecule generic competition
PROVIGIL	Modafinil	Tablet	Mature generic market
WAKIX	Pitolisant	Tablet	Small-molecule product with different mechanism and patent estate
Xyrem/Xywav	Sodium oxybate or mixed oxybates	Oral solution	More complex distribution, handling, and formulation profile

SUNOSI has a simpler dosage form than liquid oxybate products and a less mature generic environment than modafinil or armodafinil. Its commercial position depends on efficacy, tolerability, reimbursement, and the timing of generic entry.

What is the revenue exposure from generic SUNOSI entry?

SUNOSI revenue exposure is concentrated in a single small-molecule product with two tablet strengths and two principal indications. Generic entry would likely pressure net price, specialty-pharmacy economics, and formulary positioning.

The impact would depend on:

• Number of approved ANDA competitors
• Whether a first generic launches before broad competition
• Payer substitution policies
• Jazz’s contracting and authorized-generic strategy
• Patient persistence and prescriber loyalty
• Availability of competing wake-promoting products
• The extent of remaining patent protection

A conventional excipient platform reduces the technical cost of entry. That makes the product more vulnerable to multiple generic applicants once patent constraints are removed.

What is the FDA and Orange Book status of SUNOSI?

SUNOSI remains an FDA-approved prescription product for its labeled indications. Its regulatory status is that of a small-molecule NDA product, not a biologic or interchangeable product. The Orange Book is the controlling public source for current listed patents, use codes, exclusivity entries, and reference-product information.[3]

The key diligence points are:

• Current Orange Book patent numbers
• Listed patent expiration dates
• Use codes
• Any pediatric exclusivity
• ANDA applicant status
• First-filer status
• Litigation records under the Hatch-Waxman framework
• Any FDA approval of a generic or authorized generic

Patent expiry should be assessed at the claim and listing level. The expiration date of the active-ingredient patent is not necessarily the same as the expiry date of a later method-of-use or formulation patent.

Key Takeaways

• SUNOSI is a solriamfetol hydrochloride immediate-release tablet approved in 2019.
• Its public excipient profile uses standard oral-solid-dose materials: mannitol, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, and iron oxide yellow.
• The strongest commercial opportunity is generic tablet development supported by qualified excipient grades and controlled-substance manufacturing capability.
• NCE exclusivity expired on June 17, 2024, but patent and litigation barriers can still delay generic approval.
• No public basis supports treating a novel excipient system as the main SUNOSI barrier.
• Biosimilar competition is irrelevant because solriamfetol is a small molecule.
• Formulation differentiation could support orally disintegrating, sprinkle, adherence, or specialty-packaging products, but each option adds regulatory and development requirements.
• Controlled-substance compliance, API sourcing, dissolution matching, and Orange Book patent analysis are the principal entry issues.

FAQs

Can a generic SUNOSI manufacturer use the same excipients?

Yes. Generic manufacturers can generally use the same inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements. The manufacturer does not need to copy undisclosed manufacturing parameters.

Is SUNOSI an extended-release formulation?

No. SUNOSI is marketed as an immediate-release tablet. Its formulation strategy therefore centers on rapid disintegration, dissolution control, and dose uniformity rather than extended-release matrix technology.

Could an excipient supplier patent a SUNOSI-specific formulation?

Potentially, if the supplier develops a novel composition or process with patentable technical characteristics. Commodity use of mannitol, cellulose, croscarmellose sodium, magnesium stearate, silica, and iron oxide would not normally create product-specific exclusivity.

Does SUNOSI require a biosimilar application?

No. Solriamfetol is a chemically synthesized small molecule. A competing manufacturer would generally use the ANDA pathway for a generic product, not the biosimilar pathway.

What is the most attractive commercial format for a SUNOSI challenger?

The most practical format is a matched 75 mg and 150 mg immediate-release tablet line with reproducible scoring, competitive dissolution, controlled-substance manufacturing, and specialty-pharmacy distribution. An orally disintegrating or sprinkle formulation may offer differentiation but carries higher development and regulatory cost.

References

1. U.S. Food and Drug Administration. (2019). SUNOSI (solriamfetol) prescribing information and approval materials. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf

2. National Library of Medicine. (n.d.). DailyMed: SUNOSI- solriamfetol hydrochloride tablet. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules. https://www.deadiversion.usdoj.gov/schedules/